PMKB
PMKB
Genes
Variants
Interpretations
Tumor Types
Primary Sites
Activity
Login
MET
Information
View History
Pending Review
Interpretation 2217
Tier 1
MET
Variants
MET D1010Y
MET D1010N
MET D1010H
Primary Sites
Lung
Tumor Types
Non-Small Cell Lung Carcinoma
Interpretation
Crizotinib
Citations
Paik PK, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015;5(8):842-9
Awad MM, et al. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol 2016;34(7):721-30
Frampton GM, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015;5(8):850-9
Last updated: 2018-04-18 14:42:54 UTC
PMKB Bot
Genes
Variants
Interpretations
Tumor Types
Primary Sites
Activity